Yüklüyor......
Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
Rucaparib camsylate (CO-338, AG-014699, PF-01367338) is a potent PARP-1, PARP-2, and PARP-3 inhibitor. Phase I and II studies demonstrated clinical efficacy in both BRCA-mutated (inclusive of germline and somatic) ovarian tumors and ovarian tumors with homologous recombination deficiency (HRD) loss...
Kaydedildi:
| Yayımlandı: | Onco Targets Ther |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove Medical Press
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5488752/ https://ncbi.nlm.nih.gov/pubmed/28790837 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S114714 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|